keyword
MENU ▼
Read by QxMD icon Read
search

HBsAg seroconversion

keyword
https://www.readbyqxmd.com/read/28211135/the-role-of-peginterferon-in-nucleos-t-ide-analogue-treated-chronic-hepatitis-b-patients-a-review-of-published-literature
#1
Wenhong Zhang, Qing Xie, Qin Ning, Xiaoguang Dou, Xinyue Chen, Jidong Jia, Yi Xie, Hong Ren
Chronic hepatitis B infection (CHB) causes up to 1.0 million deaths annually. Currently, more than 90% of CHB patients worldwide are receiving indefinite nucleos(t)ide analogue (NA) therapy. New strategies for optimizing hepatitis B surface antigen (HBsAg) loss are required for NA-treated patients as the majority are unable to achieve HBsAg loss and may require lifelong therapy. In hepatitis B e antigen (HBeAg)-positive patients, switching from NAs to finite peginterferon (PegIFN) therapy can double HBeAg seroconversion rates...
February 17, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28207518/virological-and-serological-features-of-acute-hepatitis-b-in-adults
#2
Xiaofei Du, Yali Liu, Lina Ma, Junfeng Lu, Yi Jin, Shan Ren, Zhimin He, Xinyue Chen
Various viral kinetics among patients with acute hepatitis B (AHB) have been observed in clinical practice. This study investigated the virological, biochemical, and serological characteristics of AHB in adults.A total of 192 adult patients with AHB were recruited between December 2010 and January 2014. The quantification of biochemical and serologic markers for hepatitis B virus (HBV) infection was monitored from the onset.Of the 192 patients, 113 patients were followed up. One patient died due to acute liver failure, 2 developed chronic HBV infection...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28199034/hepatitis-b-surface-antigen-reduction-by-switching-from-long-term-nucleoside-nucleotide-analog-administration-to-pegylated-interferon
#3
Nobuharu Tamaki, Masayuki Kurosaki, Atsunori Kusakabe, Etsuro Orito, Kouji Joko, Yuji Kojima, Hiroyuki Kimura, Yasushi Uchida, Chitomi Hasebe, Yasuhiro Asahina, Namiki Izumi
Hepatitis B surface antigen (HBsAg) reduction during nucleoside/nucleotide analog (NA) therapy is slow and an alternative strategy for patients receiving ongoing NA to facilitate HBsAg reduction is required. We investigated whether switching to pegylated interferon (PEG-IFN) after long-term NA administration enhances HBsAg reduction. Forty-nine patients who switched from long-term NA to 48 weeks of PEG-IFN alfa-2a were studied. The mean duration of previous NA was 48 months (sequential group). A total of 147 patients who continued NA and matched for baseline characteristics were analyzed for comparison (NA continuation group)...
February 15, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28195558/elevated-pre-treatment-il-18-level-is-associated-with-hbeag-seroconversion-in-hiv-hbv-coinfection
#4
Yijia Li, Jing Xie, Huanling Wang, Yang Han, Nidan Wang, Chloe L Thio, Taisheng Li
BACKGROUND: In hepatitis B virus (HBV) infected patients, hepatitis B e antigen (HBeAg) seroconversion is associated with better outcomes. Interleukin-18 (IL-18) controls hepatitis B replication in a mouse model. However, its role in treatment response in HIV/HBV co-infected patients is unknown. METHODS: We enrolled 35 treatment-naïve, HBeAg positive, HIV/HBV co-infected patients. HBV DNA, HIV RNA, CD4 cell count, HBV surface antigen (HBsAg) quantification (qHBsAg), HBeAg quantification (qHBeAg) and IL-18 levels were measured prior to, at 24 and 48 weeks of HBV-active combination antiretroviral therapy (cART)...
February 14, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28183162/management-of-antiviral-resistance-in-chronic-hepatitis-b
#5
REVIEW
Young-Suk Lim
The primary goal of therapy for chronic hepatitis B (CHB) is to prevent liver disease progression. Hepatitis B surface antigen (HBsAg) seroclearance or seroconversion is regarded as an optimal endpoint to discontinue treatment. However, HBsAg seroclearance occurs very rarely with nucleos(t)ide analog (NUC) treatment, and long-term, almost indefinite, NUC treatment is required for the majority of patients. In patients with drug-resistant hepatitis B virus (HBV), a combination of tenofovir disoproxil fumarate (TDF) and entecavir (ETV), which is currently regarded as the strongest combination therapy against HBV, would be potentially safe to prevent the emergence of additional HBV resistance mutations...
February 13, 2017: Gut and Liver
https://www.readbyqxmd.com/read/28165437/relationship-of-recovered-hepatitis-b-infection-with-appearance-of-toxic-propylthiouracil-hepatitis
#6
Lejla Čalkić, Lejla Bajramović-Omeragić
Aim To investigate the relationship between recovered hepatitis B infection with appearance of toxic propylthiouracil (PTU) hepatitis and point out the growing importance of the use of drugs in the development of hepatitis. Methods A case of a 45-year-old female patient with suspicion of acute viral hepatitis who had polypragmasy of drugs in the last ten years, due to the polymorphism of symptoms/illnesses (diabetes mellitus, depression, hypertension, hypothyroidism) was presented. Results A female patient had hyperthyroidism after resolved viral hepatitis B with HBsAg seroconversion (HBsAg negative, antiHBs positive)...
February 1, 2017: Medicinski Glasnik
https://www.readbyqxmd.com/read/28078526/effectiveness-and-safety-of-entecavir-or-tenofovir-in-a-spanish-cohort-of-chronic-hepatitis-b-patients-validation-of-the-page-b-score-to-predict-hepatocellular-carcinoma
#7
Mar Riveiro-Barciela, David Tabernero, José L Calleja, Sabela Lens, María L Manzano, Francisco Gea Rodríguez, Javier Crespo, Belén Piqueras, Juan M Pascasio, Carmen Comas, Maria L Gutierrez, Alberto Aguirre, Emilio Suárez, Javier García-Samaniego, Miguel Rivero, Doroteo Acero, Miguel Fernandez-Bermejo, Diego Moreno, Pilar Sánchez-Pobre, Beatriz de Cuenca, J J Moreno-Palomares, Rafael Esteban, Maria Buti
BACKGROUND: Long-term antiviral therapy has resulted in viral suppression and biochemical response in chronic hepatitis B, although the risk of hepatocellular carcinoma has not been abolished. The Page-B score could be useful to estimate the probability of HCC. AIMS: To analyze the effectiveness and safety of entecavir or tenofovir for more than 4 years and the usefulness of Page-B score in the real-world setting. METHODS: Analysis of Caucasian chronic hepatitis B subjects treated with entecavir or tenofovir from the prospective, multicenter database CIBERHEP...
January 11, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28052620/when-can-we-stop-nucleoside-analogues-in-patients-with-chronic-hepatitis-b
#8
REVIEW
Chern Hao Chong, Seng Gee Lim
Treatment with nucleoside analogue (NAs) is now the most common treatment for chronic hepatitis B (CHB) and is recommended by all guidelines. Stopping NAs is a controversial issue in these patients, unless the clinical endpoints of HBeAg seroconversion or HBsAg seroclearance are achieved. While HBeAg seroconversion can occur in a significant number of patients, HBsAg seroclearance rates are low. HBsAg seroclearance is increasingly accepted as the ideal end of treatment, representing a functional cure. Treatment withdrawal leads to relapse in 50% of patients who achieve HBeAg seroconversion and complete at least 12 months of consolidation therapy...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28028369/effect-of-switching-from-treatment-with-nucleos-t-ide-analogs-to-pegylated-interferon-%C3%AE-2a-on-virological-and-serological-responses-in-chronic-hepatitis-b-patients
#9
Li-Ting He, Xiao-Guang Ye, Xiao-Yuan Zhou
AIM: To investigate the efficacy of switching to pegylated interferon-α-2a (PegIFNα-2a) treatment in nucleos(t)ide analog (NA)-treated chronic hepatitis B (CHB) responder patients. METHODS: A 48-wk prospective and retrospective treatment trial of NA-treated CHB patients who had received entecavir (ETV) for at least 48 wk and had serum hepatitis B virus (HBV)-DNA < 500 IU/mL, serum hepatitis B envelope antigen (HBeAg) < 100 S/CO, serum alanine aminotransferase, and aspartate aminotransferase levels < 2 × the upper limit of normal of 40 IU/L was performed...
December 14, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28005687/response-to-tenofovir-among-lamivudine-experienced-hepatitis-b-and-hiv-coinfected-adolescents
#10
Linda Aurpibul, Pagakrong Lumbiganon, Rawiwan Hansudewechakul, Suparat Kanjanavanit, Torsak Bunupuradah, Pope Kosalaraksa, Pawinee Taeprasert, Thanyawee Puthanakit
We determined hepatitis B virus (HBV) suppression rates among 18 lamivudine (3TC)-experienced HBV-HIV coinfected adolescents after treatment with tenofovir disoproxil fumurate (TDF). At TDF initiation, their median age was 17.6 years, and duration of 3TC-exposure was 7.3 years. Eleven patients (61%) achieved HBV DNA <60 IU/mL after 48 weeks on TDF and 3TC which was similar to adult studies, although HBsAg loss or HBeAb seroconversion did not occur.
December 21, 2016: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27936480/treatment-of-fulminant-acute-hepatitis-b-with-nucles-t-id-analogues-is-safe-and-does-not-lead-to-secondary-chronification-of-hepatitis-b
#11
C Jochum, F Maischack, O E Anastasiou, J Verheyen, J Timm, L Bechmann, G Gerken, A Canbay
Background: Acute hepatitis B virus (HBV) infection is still a major cause of acute liver failure (ALF), necessitating a high rate of emergency liver transplantation (LTx). Acute infection is followed by high viral replication rates leading to hepatocyte death and, ultimately, ALF. The objective of treating HBV-induced ALF thus is to eliminate, or significantly suppress, HBV replication and therefore reduce cell death and support regeneration. Objective: In this retrospective study, we want to evaluate the timing, the safety, and the long-term virological outcome of this approach...
December 2016: Zeitschrift Für Gastroenterologie
https://www.readbyqxmd.com/read/27917266/telbivudine-vs-tenofovir-in-hepatitis-b-e-antigen-negative-chronic-hepatitis-b-patients-optima-roadmap-study
#12
Zahari Krastev, Diana Petrova, Iskren Kotzev, Mustafa Kemal Celen, Meryl Mendelson, Richa Chandra, Priti Pandey, Kamal Hamed
AIM: To make efficacy and safety comparison of telbivudine-raodmap and tenofovir-roadmap in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. METHODS: This was the first prospective, randomised, two-arm, open-label, non-inferiority study in HBeAg-negative CHB patients that compared telbivudine and tenofovir administered as per roadmap concept. Patients were treated up to 24 wk and, depending on virologic response, continued the same therapy or received add-on therapy up to 104 wk...
November 18, 2016: World Journal of Hepatology
https://www.readbyqxmd.com/read/27862721/efficacy-and-safety-of-tenofovir-disoproxil-fumarate-rescue-therapy-for-chronic-hepatitis-b-patients-who-failed-other-nucleos-t-ide-analogs
#13
Hiromitsu Kumada, Kazuhiko Koike, Kazuaki Suyama, Hiroshi Ito, Hiroshi Itoh, Wataru Sugiura
AIM: Acquisition of nucleos(t)ide analog (NA) inhibitor resistance is critical in successful chronic hepatitis B treatment. As the pattern of tenofovir disoproxil fumarate (TDF) resistance mutations differs from that of other antiviral drugs, we sought to clarify the salvaging potential of TDF in patients with hepatitis B virus (HBV) infection who are poor responders or resistant to other NAs. METHODS: A prospective, multicenter, single-arm, open-label study was carried out from December 2011 to October 2014...
November 15, 2016: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/27855500/treatment-of-hepatitis-b-virus-an-update
#14
Haley Ward, Lydia Tang, Bhawna Poonia, Shyam Kottilil
Chronic hepatitis B virus infection is a global health concern as it affects over 240 million people worldwide and an estimated 686,000 people die annually as a result of complications of the disease. With the development of newer antiviral drugs, viral suppression of HBV is achievable, however elimination of HBV from infected individuals (functional cure) remains an issue. Due to persistence of HBV DNA (cccDNA) in infected cells, chronically infected patients who discontinue therapy prior to HBsAg loss or seroconversion are likely to relapse...
December 2016: Future Microbiology
https://www.readbyqxmd.com/read/27793564/role-of-hbsag-decline-in-patients-with-chronic-hepatitis-b-hbeag-negative-and-e-genotype-treated-with-pegylated-interferon
#15
Lucio Boglione, Jessica Cusato, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio
Treatment options for patients with chronic hepatitis B (CHB) and hepatitis B e antigen (HBeAg)-negative are pegylated interferon alfa-2a (PEG-IFN) for 48 weeks or nucleos(t)ide analogues (NAs). The choice of patients with higher chance of sustained response (SR) to PEG-IFN can be made with pre-treatment and on-treatment factors; recent studies evidenced the role of early drop of serum hepatitis B surface antigen (HBsAg) as predictor of SR. The aim of this study was the evaluation of early decrease of HBsAg on the SR in HBeAg-negative patients with E genotype...
October 26, 2016: Antiviral Research
https://www.readbyqxmd.com/read/27793166/hbsag-and-hbeag-in-the-prediction-of-a-clinical-response-to-peginterferon-%C3%AE-2b-therapy-in-chinese-hbeag-positive-patients
#16
Song Yang, Huichun Xing, Yuming Wang, Jinlin Hou, Duande Luo, Qing Xie, Qin Ning, Hong Ren, Huiguo Ding, Jifang Sheng, Lai Wei, Shijun Chen, Xiaoling Fan, Wenxiang Huang, Chen Pan, Zhiliang Gao, Jiming Zhang, Boping Zhou, Guofeng Chen, Mobin Wan, Hong Tang, Guiqiang Wang, Yuxiu Yang, Dongping Xu, Peiling Dong, Qixin Wang, Jue Wang, Fernando A Bognar, Daozhen Xu, Jun Cheng
BACKGROUND: This study aimed to evaluate the predictive values of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) levels in 171 Chinese patients with chronic hepatitis B who received a 48-week course of pegylated interferon alfa-2b therapy at 1.5 mcg/kg. METHODS: HBsAg, HBeAg, and hepatitis B virus (HBV) DNA levels were measured at baseline and weeks 12, 24, 48, and 72. Clinical responses were defined as a combined response (CR, HBeAg seroconversion [sustained response, SR] combined with HBV DNA level <2,000 IU/mL at week 72)...
October 28, 2016: Virology Journal
https://www.readbyqxmd.com/read/27769101/antiviral-response-is-not-sustained-after-cessation-of-lamivudine-treatment-in-chronic-hepatitis-b-patients-a-10-year-follow-up-study
#17
Seong Hee Kang, Keunhee Kang, Yeon Jong Eun, Young Sun Lee, Tae Suk Kim, Yang Jae Yoo, Sang Jun Suh, Eileen L Yoon, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Kwan Soo Byun
Although the ideal end point for antiviral treatment in patients with chronic hepatitis B (CHB) is loss of HBsAg, the typical clinical end points are HBeAg seroconversion in HBeAg-positive patients and long-term DNA suppression in HBeAg-negative patients. We evaluated the long-term antiviral response after cessation of lamivudine treatment in CHB patients. A total of 157 patients who had discontinued lamivudine between 1997 and 2014 were enrolled (97 HBeAg-positive and 60 HBeAg-negative CHB patients). The long-term durability of the antiviral response (viralogical relapse; HBV DNA ≥10(4)  copies/ml) and the clinical course of these patients were analyzed retrospectively...
October 21, 2016: Journal of Medical Virology
https://www.readbyqxmd.com/read/27687670/-hbsag-seroconversion-after-entecavir-therapy-for-7-years-following-a-poor-response-to-interferon-%C3%AE-2b-monotherapy-in-a-hbeag-negative-patient-with-chronic-hepatitis-b
#18
Tao-Yuan Li, You-Peng Chen
We report a rare case of HBsAg seroconversion after 7 years of entecavir therapy in a 48-year-old HBeAg-negative CHB male patient with chronic hepatitis B (CHB). After a poor response to a 48-week interferon-α 2b therapy, the patient received long-term entecavir therapy. Serum ALT levels became normal and HBV DNA viral load was undetectable at the 10th week after commencement of entecavir treatment, and seroconversion of HBsAg was detected after 7 years of entecavir therapy.
August 20, 2016: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/27647214/prevalence-of-hepatitis-b-surface-antigen-hbsag-in-a-blood-donor-population-born-prior-to-and-after-implementation-of-universal-hbv-vaccination-in-shenzhen-china
#19
Zhen Wang, Jinfeng Zeng, Tingting Li, Xin Zheng, Xiaoxuan Xu, Xianlin Ye, Liang Lu, Weigang Zhu, Baocheng Yang, Jean-Pierre Allain, Chengyao Li
BACKGROUND: Neonatal hepatitis B vaccination program at birth has been implemented nationwide since 1992 in China. However, current HBV prevalence status in blood donors has not been entirely examined, which may impact HBV safety in blood donations as the vaccinees over 18 years old progressively become the majority population of blood donors. METHODS: In this study, 569,145 blood donors were screened for HBsAg by rapid tests and enzyme immunoassays, among them 475,538 blood samples with negative HBsAg were further screened for HBV DNA by nucleic acid testing between 2005 and 2014 at Shenzhen blood center...
2016: BMC Infectious Diseases
https://www.readbyqxmd.com/read/27545497/tenofovir-disoproxil-fumarate-tdf-vs-emtricitabine-ftc-tdf-in-lamivudine-resistant-hepatitis-b-a-5-year-randomised-study
#20
Scott Fung, Peter Kwan, Milotka Fabri, Andrzej Horban, Mijomir Pelemis, Hie-Won Hann, Selim Gurel, Florin A Caruntu, John F Flaherty, Benedetta Massetto, Kyungpil Kim, Kathryn M Kitrinos, G Mani Subramanian, John G McHutchison, Leland J Yee, Magdy Elkhashab, Thomas Berg, Ioan Sporea, Cihan Yurdaydin, Petr Husa, Maciej S Jablkowski, Edward Gane
BACKGROUND & AIMS: Long-term treatment with tenofovir disoproxil fumarate (TDF) alone, or in combination with emtricitabine (FTC) is associated with sustained viral suppression in patients with lamivudine resistant (LAM-R) chronic hepatitis B (CHB). METHODS: LAM-R CHB patients were randomised 1:1 to receive TDF 300mg or FTC 200mg and TDF 300mg once daily in a prospective, double blind, study. The proportion of patients with plasma hepatitis B virus (HBV) DNA<69IU/ml (<400copies/ml) at week 96 (primary efficacy endpoint) was reported previously...
January 2017: Journal of Hepatology
keyword
keyword
31626
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"